141 related articles for article (PubMed ID: 18761891)
21. Final analysis of a study assessing genital human papillomavirus genoprevalence in young Australian women, following eight years of a national vaccination program.
Garland SM; Cornall AM; Brotherton JML; Wark JD; Malloy MJ; Tabrizi SN;
Vaccine; 2018 May; 36(23):3221-3230. PubMed ID: 29724506
[TBL] [Abstract][Full Text] [Related]
22. Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial.
Neuzil KM; Canh DG; Thiem VD; Janmohamed A; Huong VM; Tang Y; Diep NT; Tsu V; LaMontagne DS
JAMA; 2011 Apr; 305(14):1424-31. PubMed ID: 21486975
[TBL] [Abstract][Full Text] [Related]
23. Effect of the decision-making process in the family on HPV vaccination rates among adolescents 9-17 years of age.
Berenson AB; Laz TH; Hirth JM; McGrath CJ; Rahman M
Hum Vaccin Immunother; 2014; 10(7):1807-11. PubMed ID: 25424786
[TBL] [Abstract][Full Text] [Related]
24. Low prevalence of vaccine-type HPV infections in young women following the implementation of a school-based and catch-up vaccination in Quebec, Canada.
Goggin P; Sauvageau C; Gilca V; Defay F; Lambert G; Mathieu-C S; Guenoun J; Comète E; Coutlée F
Hum Vaccin Immunother; 2018 Jan; 14(1):118-123. PubMed ID: 29049007
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
[TBL] [Abstract][Full Text] [Related]
26. Impact of partial bivalent HPV vaccination on vaccine-type infection: a population-based analysis.
Cuschieri K; Kavanagh K; Moore C; Bhatia R; Love J; Pollock KG
Br J Cancer; 2016 May; 114(11):1261-4. PubMed ID: 27115467
[TBL] [Abstract][Full Text] [Related]
27. Human papillomavirus vaccination coverage, policies, and practical implementation across Europe.
Nguyen-Huu NH; Thilly N; Derrough T; Sdona E; Claudot F; Pulcini C; Agrinier N;
Vaccine; 2020 Feb; 38(6):1315-1331. PubMed ID: 31836255
[TBL] [Abstract][Full Text] [Related]
28. Vaccination against HPV virus: a systematic review of economic evaluation studies for developed countries.
Kostaras D; Karampli E; Athanasakis K
Expert Rev Pharmacoecon Outcomes Res; 2019 Apr; 19(2):147-158. PubMed ID: 30501434
[TBL] [Abstract][Full Text] [Related]
29. Status of HPV vaccine introduction and barriers to country uptake.
Gallagher KE; LaMontagne DS; Watson-Jones D
Vaccine; 2018 Aug; 36(32 Pt A):4761-4767. PubMed ID: 29580641
[TBL] [Abstract][Full Text] [Related]
30. Canadian school-based HPV vaccine programs and policy considerations.
Shapiro GK; Guichon J; Kelaher M
Vaccine; 2017 Oct; 35(42):5700-5707. PubMed ID: 28893472
[TBL] [Abstract][Full Text] [Related]
31. Human Papillomavirus Infection and Vaccination.
Valentino K; Poronsky CB
J Pediatr Nurs; 2016; 31(2):e155-66. PubMed ID: 26586310
[TBL] [Abstract][Full Text] [Related]
32. HPV vaccine introduction in Rwanda: Impacts on the broader health system.
Torres-Rueda S; Rulisa S; Burchett HE; Mivumbi NV; Mounier-Jack S
Sex Reprod Healthc; 2016 Mar; 7():46-51. PubMed ID: 26826045
[TBL] [Abstract][Full Text] [Related]
33. Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: a transmission-dynamic modelling study.
Laprise JF; Drolet M; Boily MC; Jit M; Sauvageau C; Franco EL; Lemieux-Mellouki P; Malagón T; Brisson M
Vaccine; 2014 Oct; 32(44):5845-53. PubMed ID: 25131743
[TBL] [Abstract][Full Text] [Related]
34. Attitudes, Knowledge and Factors Associated with Human Papillomavirus (HPV) Vaccine Uptake in Adolescent Girls and Young Women in Victoria, Australia.
Tung IL; Machalek DA; Garland SM
PLoS One; 2016; 11(8):e0161846. PubMed ID: 27564213
[TBL] [Abstract][Full Text] [Related]
35. Variation in adult vaccination policies across Europe: an overview from VENICE network on vaccine recommendations, funding and coverage.
Kanitz EE; Wu LA; Giambi C; Strikas RA; Levy-Bruhl D; Stefanoff P; Mereckiene J; Appelgren E; D'Ancona F;
Vaccine; 2012 Jul; 30(35):5222-8. PubMed ID: 22721901
[TBL] [Abstract][Full Text] [Related]
36. Human Papillomavirus Vaccination Coverage Among School Girls in a Demonstration Project - Botswana, 2013.
Raesima MM; Forhan SE; Voetsch AC; Hewitt S; Hariri S; Wang SA; Pelletier AR; Letebele M; Pheto T; Ramogola-Masire D; El-Halabi S
MMWR Morb Mortal Wkly Rep; 2015 Oct; 64(40):1147-9. PubMed ID: 26468997
[TBL] [Abstract][Full Text] [Related]
37. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.
Rogovskaya SI; Shabalova IP; Mikheeva IV; Minkina GN; Podzolkova NM; Shipulina OY; Sultanov SN; Kosenko IA; Brotons M; Buttmann N; Dartell M; Arbyn M; Syrjänen S; Poljak M
Vaccine; 2013 Dec; 31 Suppl 7():H46-58. PubMed ID: 24332297
[TBL] [Abstract][Full Text] [Related]
38. Coverage of the English national human papillomavirus (HPV) immunisation programme among 12 to 17 year-old females by area-level deprivation score, England, 2008 to 2011.
Hughes A; Mesher D; White J; Soldan K
Euro Surveill; 2014 Jan; 19(2):. PubMed ID: 24457007
[TBL] [Abstract][Full Text] [Related]
39. Asking about human papillomavirus vaccination and the usefulness of registry validation: a study of young women recruited using Facebook.
Gunasekaran B; Jayasinghe Y; Brotherton JM; Fenner Y; Moore EE; Wark JD; Fletcher A; Tabrizi SN; Garland SM
Vaccine; 2015 Feb; 33(6):826-31. PubMed ID: 25444782
[TBL] [Abstract][Full Text] [Related]
40. Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program.
Osborne SL; Tabrizi SN; Brotherton JM; Cornall AM; Wark JD; Wrede CD; Jayasinghe Y; Gertig DM; Pitts MK; Garland SM;
Vaccine; 2015 Jan; 33(1):201-8. PubMed ID: 25444787
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
